Ventria Bioscience Invited to Present ExpressTec (TM) at the 4th International Plant-Based Vaccines & Antibodies Conference
|| Print ||
|Monday, 06 June 2011 17:35 (UTC + 2)|
ExpressTec™ is a plant-based manufacturing technology that enables safe, affordable, and sustainable production of biologics.
At the conference, Ventria Bioscience will discuss its experience scaling up a plant-based cGMP manufacturing system to commercial scale exceeding 1,000 kilograms of recombinant protein. To accomplish this scale, Ventria employs its proprietary recombinant protein manufacturing technology called ExpressTec™. ExpressTec™ provides a safe, affordable, and sustainable manufacturing platform that produces target protein yields more than ten times higher than alternative systems.
“Ventria is the first company to commercialize recombinant proteins derived from a plant-based manufacturing system and has proven this technology at large scale,” said Scott Deeter, President and CEO for Ventria Bioscience. “ExpressTec™ achieves protein yields, cost-effectiveness and safety advantages that are the foundation of a portfolio of products that were previously not available to a global customer base.”